Premera Bluecross atopic dermatitis Coverage Update

Coverage Criteria — Atopic Dermatitis Therapies

Aryl Hydrocarbon Receptor (AhR) Agonist — Vtama (tapinarof) topical (medical necessity)

Covered when ALL of the following are met

Vtama criteria: Individual is aged >=2 years; has had an inadequate response or intolerance to one topical corticosteroid medication (exception allowed for face or genital involvement); has had an inadequate response or intolerance to one topical calcineurin inhibitor medication (e.g., pimecrolimus or tacrolimus).age >=2

Documentation required

Calcineurin inhibitors — Elidel (pimecrolimus) and Protopic (tacrolimus) (medical necessity)

Covered when ALL of the following are met

Calcineurin inhibitor criteria: Individual is aged >=2 years; has had an inadequate response or intolerance to one topical corticosteroid medication (exception allowed for face or genital involvement); has tried both generic pimecrolimus and generic tacrolimus and had inadequate response or intolerance to both (documentation required).age >=2

Trials of generics required; documentation required

Interleukin-13 antagonist — Adbry (tralokinumab-Idrm) (medical necessity)

Covered when ALL of the following are met

Adbry criteria: Individual is aged >=12 years; has a diagnosis of atopic dermatitis involving >=10% body surface area (BSA) (Exception: may be granted for extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement that interferes with sexual function); has had an inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus); has had an inadequate response or intolerance to one high‑potency topical corticosteroid (e.g., betamethasone dipropionate, mometasone furoate, fluocinonide, or clobetasol propionate) (exception allowed for face/genital involvement); medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist; maintenance dose per policy (300 mg every other [dose interval specified in full policy]).age >=12; BSA >=10%

Prescribing specialty and maintenance dosing per policy; documentation required

Interleukin-13 antagonist — Ebglyss (lebrikizumab-Ibkz) (medical necessity)

Covered when ALL of the following are met

Ebglyss criteria: Individual is aged >=12 years; has a diagnosis of atopic dermatitis involving >=10% body surface area (BSA) (Exception: may be granted for extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement that interferes with sexual function); has had an inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus); has had an inadequate response or intolerance to one high‑potency topical corticosteroid (e.g., betamethasone dipropionate, mometasone furoate, fluocinonide, or clobetasol propionate) (exception allowed for face/genital involvement); medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist; maintenance dose per policy (e.g., 250 mg every 4 [dose interval specified in full policy]).age >=12; BSA >=10%

Prescribing specialty and maintenance dosing per policy; documentation required

Interleukin-31 antagonist — Nemluvio (nemolizumab-ilto) (medical necessity)

Covered when ALL of the following are met

Nemluvio criteria for AD: Individual is aged >=12 years; has a diagnosis of atopic dermatitis involving >=10% body surface area (BSA) (Exception: may be granted for extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement that interferes with sexual function); has had an inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus); has had an inadequate response or intolerance to one high‑potency topical corticosteroid (e.g., betamethasone dipropionate, mometasone furoate, fluocinonide, or clobetasol propionate) (exception allowed for face/genital involvement); has had an inadequate response or intolerance to tralokinumab (Adbry), dupilumab (Dupixent), lebrikizumab (Ebglyss), OR upadacitinib (Rinvoq); medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist; maintenance dose limited per policy (e.g., 30 mg every 4 weeks).age >=12; BSA >=10%

Also has separate prurigo nodularis criteria; documentation required

Nemluvio for prurigo nodularis (PN)

Covered when ALL of the following are met

Nemluvio PN criteria: Individual is aged >=18 years; has >=20 identifiable nodular lesions in total; has experienced pruritus for >=6 weeks; has tried at least one high‑ or super‑high‑potency prescription topical corticosteroid for >=14 consecutive days and had inadequate response or intolerance; has had an inadequate response or intolerance to dupilumab (Dupixent); medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist; maintenance dose limited per policy (e.g., 60 mg every 4 weeks).age >=18; nodules >=20; pruritus >=6 weeks

Dose instruction and trial durations per policy; documentation required

Janus kinase (JAK) inhibitors — Cibinqo (abrocitinib) and Rinvoq (upadacitinib) (medical necessity)

Covered when ALL of the following are met

JAK inhibitor criteria: Individual is aged >=12 years; has a diagnosis of atopic dermatitis involving >=10% body surface area (BSA) (Exception: may be granted for extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement that interferes with sexual function); has had an inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus); has had an inadequate response or intolerance to one high‑potency topical corticosteroid (e.g., betamethasone dipropionate, mometasone furoate, fluocinonide, or clobetasol propionate) (exception allowed for face/genital involvement); has had an inadequate response or intolerance to one traditional systemic therapy (e.g., methotrexate, azathioprine, cyclosporine, mycophenolate mofetil) — except that an individual who has already tried tralokinumab, dupilumab, lebrikizumab, or Nemluvio is not required to 'step back' and try a traditional systemic agent; medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist.age >=12; BSA >=10%

Some exceptions allow bypassing certain step therapy; documentation required

Topical JAK inhibitor — Opzelura (ruxolitinib) (medical necessity)

Covered when ALL of the following are met

Opzelura criteria: Individual is aged >=12 years; is not immunocompromised; has had an inadequate response or intolerance to one topical corticosteroid medication (exception allowed for face or genital involvement); has had an inadequate response or intolerance to one topical calcineurin inhibitor medication (e.g., pimecrolimus or tacrolimus); intended for topical, short‑term, non‑continuous chronic treatment of mild to moderate atopic dermatitis; medication prescribed by or in consultation with an allergist, immunologist, or dermatologist; use for vitiligo is considered cosmetic and not covered by this policy.age >=12

Vitiligo use cosmetic exclusion; long‑term pediatric/sensitive‑area data limited

Phosphodiesterase-4 inhibitors — Eucrisa (crisaborole) and Zoryve (roflumilast) (medical necessity)

Covered when ALL of the following are met

PDE4 inhibitor criteria: Eucrisa (crisaborole): individual is aged >=3 months; has had an inadequate response or intolerance to one topical corticosteroid medication (exception allowed for face or genital involvement); for individuals aged >=2 years, has had an inadequate response or intolerance to one topical calcineurin inhibitor. Zoryve (roflumilast) 0.15% cream: individual is aged >=6 years; has had an inadequate response or intolerance to one topical corticosteroid medication (exception allowed for face or genital involvement); has had an inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus). Medication prescribed by or in consultation with an allergist, immunologist, or dermatologist.age thresholds vary (Eucrisa >=3 months; Zoryve >=6 years)

Prescribing specialty and age‑based requirements per product labeling; documentation required

Treatment approach

Guideline-based stepwise approach (per AAD referenced):

Core stepwise care: Avoidance of triggers; basic skin care and regular moisturization; if inadequate, use topical corticosteroids; topical calcineurin inhibitors may be used concurrently or as steroid‑sparing therapy; consider escalation to systemic therapies for severe disease or failure of topical agents.

AAD guideline (last updated 2014) referenced for stepwise approach

Tralokinumab evidence

Tralokinumab (Adbry) evidence summary — outcomes at Week 16:

ECZTRA trial outcomes: ECZTRA 1: at Week 16 more individuals on tralokinumab achieved IGA 0/1 vs placebo (15.8% vs 7.1%; difference 8.6%; P=0.002) and EASI‑75 (25.0% vs 12.7%; difference 12.1%; P<0.001). ECZTRA 2 and ECZTRA 3 showed similar benefits including when used with topical corticosteroids.Week 16 outcomes

Provides efficacy basis for moderate‑to‑severe AD use

Abrocitinib evidence

Abrocitinib (Cibinqo) evidence summary — pivotal trials:

Trial population and endpoints: Three randomized, double‑blind, placebo‑controlled trials (TrialAD‑1, TrialAD‑2, TrialAD‑3) in subjects >=12 years with moderate‑to‑severe AD evaluated co‑primary endpoints IGA and EASI‑75 at Week 12; trials included subjects with inadequate response to topical therapy and prior systemic therapy exposure and demonstrated rapid itch improvement (PP‑NRS4) by Week 2 for 200 mg and 100 mg doses.IGA and EASI‑75 at Week 12; PP‑NRS4 by Week 2

Trial characteristics and endpoints summarize efficacy evidence

Lebrikizumab evidence

Lebrikizumab (Ebglyss) evidence summary — pivotal trials:

Phase 3 outcomes: ADvocate1, ADvocate2, and ADhere met the primary endpoint of IGA 0/1 at Week 16 in individuals >=12 years with moderate‑to‑severe AD; safety profile was generally consistent through maintenance periods (Weeks 16–52) with low discontinuation due to adverse events.IGA 0/1 at Week 16

Maintenance safety data reported through Weeks 16–52

Crisaborole evidence

Crisaborole (Eucrisa) evidence summary — topical PDE-4 inhibitor:

Trial outcomes: Two randomized, double‑blind, vehicle‑controlled trials in subjects aged 2–79 years showed modest superiority of crisaborole applied twice daily for 28 days for ISGA success at Day 29 versus vehicle (e.g., Trial 1: 32.8% vs 25.4%; Trial 2: 31.4% vs 18.0%).ISGA success at Day 29

Population largely pediatric in the trials

Ruxolitinib evidence

Ruxolitinib (Opzelura) evidence summary — topical JAK inhibitor:

Efficacy and limitations: Ruxolitinib cream 1.5% BID demonstrated IGA response, EASI‑75, and itch improvement in double‑blind trials up to 8 weeks versus vehicle with supportive open‑label extensions up to 52 weeks; long‑term efficacy, efficacy in sensitive areas and pediatric data are less established; Phase 2 data suggest similar short‑term efficacy to triamcinolone 0.1% but not powered for definitive comparisons.8‑week double‑blind data; OL extensions ongoing

Limitations in long‑term and sensitive‑area evidence noted

Upadacitinib evidence

Upadacitinib (Rinvoq) evidence summary — oral JAK inhibitor:

Phase 3 program and results: Three Phase 3 trials (AD‑1, AD‑2, AD‑3) in individuals >=12 years evaluated upadacitinib 15 mg and 30 mg once daily versus placebo for 16 weeks; co‑primary endpoints vIGA‑AD 0/1 and EASI‑75 at Week 16 showed dose‑dependent substantial differences from placebo (e.g., AD‑1 vIGA‑AD 0/1 difference vs placebo: 15 mg = 40%; 30 mg = 54%).vIGA‑AD 0/1 and EASI‑75 at Week 16

Included monotherapy and concomitant TCS arms; population included prior systemic therapy exposure

Recent additions and revisions (summary)

Recent coverage criteria actions and requirements (summary of changes present in this document segment).

Nemluvio added: Coverage criteria for Nemluvio (nemolizumab‑ilto) were added to the policy.

Interim review 06/01/25 added criteria.

Cibinqo prior therapy requirement: Cibinqo (abrocitinib) coverage now requires inadequate response or intolerance to tralokinumab, dupilumab, lebrikizumab, or upadacitinib; limited exception allows Ebglyss or Nemluvio to substitute for one traditional systemic therapy trial.

Interim review 06/01/25.

Vtama added: Coverage criteria for Vtama (tapinarof) were added for certain individuals with atopic dermatitis.

Annual review 04/01/25.

Zoryve added:

Use of topical ruxolitinib (Opzelura) for the treatment of vitiligo is classified as a cosmetic indication and is excluded from coverage under this policy. The policy notes that ruxolitinib’s clinical trial evidence and approved indications are for atopic dermatitis, with double-blind data up to 8 weeks and ongoing extension studies; vitiligo use is expressly not covered. Providers should rely on the product’s FDA‑approved prescribing information and the policy’s exclusions when assessing requests for Opzelura for vitiligo.

Within the excerpted portion of the policy, no additional explicit exclusions beyond the cosmetic classification for ruxolitinib in vitiligo are listed. The document otherwise references standard stepwise care and agent‑specific criteria without further exclusion statements in this window.

The policy explicitly states that use of ruxolitinib (Opzelura) for vitiligo is considered cosmetic and therefore is not covered. Requests for Opzelura outside the approved atopic dermatitis indications — specifically for vitiligo — should be denied under the cosmetic exclusion noted in the policy history and coverage criteria.

All other uses of the drugs listed in this policy that fall outside the coverage criteria described herein are considered not medically necessary. The policy clarifies that investigational or non‑specified indications for Adbry, Cibinqo, Elidel, Eucrisa, Nemluvio, Opzelura, Protopic, Zoryve, Rinvoq, Vtama and related agents are investigational and not covered unless specifically outlined in the policy.

In this excerpt there are no additional explicit 'not medically necessary' statements beyond the general statement that uses not outlined in the policy are considered not medically necessary and the investigational-not‑covered designations. Reimbursement decisions should be based on the specific drug criteria in the policy and supporting documentation of medical necessity.

Coding and Body Surface Area

HCPCS codes referencedHCPCS

J3590

Unclassified biologics (use to report: Adbry)

Body Surface Area (BSA) — >= 10%

BSA threshold>= 10% body surface area (BSA) required for definition of moderate-to-severe AD (exceptions for recalcitrant facial, pustular hands/feet, or genital involvement)

ExceptionsMay be granted for extensive recalcitrant facial involvement, pustular hand/foot involvement, or genital involvement interfering with sexual function

Use in criteria setsApplied to multiple systemic and biologic therapies (eg, tralokinumab, lebrikizumab, abrocitinib, upadacitinib, nemolizumab) as an eligibility threshold

Supporting trial definitionsClinical trials cited (eg TrialAD, ECZTRA, ADvocate) used similar BSA thresholds in enrollment and endpoints

Provider Actions, Prior Authorization & Documentation

Note

Clinical evidence & prescribing information

Clinical-evidence summaries: Summaries of pivotal clinical trials and prescribing information for listed agents are provided in the policy. Key trial evidence cited includes phase 3 programs for tralokinumab (ECZTRA 1–3), abrocitinib (TrialAD-1, -2, -3), lebrikizumab (ADvocate1, ADvocate2, ADhere), ruxolitinib cream trials (8‑week DB studies with open‑label extensions), upadacitinib phase 3 trials (AD‑1, AD‑2, AD‑3), crisaborole pivotal trials, and referenced prescribing information. The excerpt does not itself add separate prior authorization rules beyond the coverage criteria; it provides clinical context supporting the medical necessity criteria.

Phase 3 randomized, double‑blind, placebo‑controlled trials and prescribing information are cited for specific agents.
Clinical trial evidence summarized supports the drug‑specific coverage criteria but the excerpt contains no additional independent PA rules.

Prior Authorization

Prior authorization & length of approval

Prior authorization required for many systemic and topical agents listed in this policy. Non‑formulary exception reviews and routine authorizations for drugs in this policy may be approved for up to 12 months for initial authorization and re‑authorization when drug‑specific criteria are met and documentation shows continued clinical benefit. Medications remain subject to member benefit routing.

Initial Therapy Requirements

Initial therapy requirements

Initial approval conditions per drug

General initial therapy: Most agents require inadequate response or intolerance to at least one topical corticosteroid and one topical calcineurin inhibitor; age and BSA thresholds apply per agent; certain systemic/biologic agents require prior trials of traditional systemic therapies or prior biologic failure as specified per drug.

Initial/topical therapy

Topical‑first approach and requirements for topical trials before systemic therapy

Topical therapy: Begin with avoidance of triggers, basic skin care and moisturization; if inadequate, use topical corticosteroids; topical calcineurin inhibitors may be used concurrently or as steroid‑sparing therapy; topical agents (e.g., crisaborole, ruxolitinib) are indicated for milder disease per product labeling and trial populations.

AAD guideline referenced (last updated 2014)

Re-authorization and Maintenance Criteria

Re-authorization criteria

Re-authorization

Re-authorization: May be approved up to 12 months if drug‑specific coverage criteria are met and chart notes demonstrate continued positive clinical response to therapy.

Continuation/maintenance

Maintenance/continuation evidence described in trials:

Continuation evidence for monoclonals: Agents such as tralokinumab and lebrikizumab included rerandomization/maintenance phases with follow‑up periods (safety follow‑up 16 weeks after last dose); lebrikizumab reported consistent safety through Weeks 16–52. Continued coverage requires documentation of continued clinical benefit per re‑authorization guidance.

Refer to individual prescribing information for agent‑specific maintenance dosing and intervals.

Step Therapy Requirements and Prior Trials

Step	Requirement
Initial topical therapy	Inadequate response or intolerance to at least one topical corticosteroid medication (exception may be granted for face/genital involvement).
Topical steroid-sparing/adjunct	Inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus). For calcineurin inhibitors, trials of both generic pimecrolimus and generic tacrolimus are required with documentation of inadequate response or intolerance before branded agents are considered.
Topical-only agents (PDE4, topical JAK, AhR agonist)	Most topical agents (for example: crisaborole, ruxolitinib, tapinarof) require the topical corticosteroid and topical calcineurin inhibitor steps above prior to coverage as specified in each product's criteria.
Systemic agent consideration	Some systemic therapies (including oral JAK inhibitors and biologics) require prior trials of traditional systemic agents (e.g., methotrexate, azathioprine, cyclosporine, mycophenolate mofetil) in addition to topical failures unless exceptions apply per individual product criteria.

When to escalate	Clinical rationale / policy direction
Persistent or severe disease despite topical care	AAD guideline–style stepwise approach recommends escalation to systemic therapies for individuals with severe atopic dermatitis or those who fail topical treatments after appropriate skin care, trigger avoidance, and use of topical corticosteroids/calcineurin inhibitors.
Failure of topical corticosteroid and topical calcineurin inhibitor	Policy requires inadequate response or intolerance to topical corticosteroids and a topical calcineurin inhibitor for most agents before escalating to systemic or targeted therapies as outlined in product-specific criteria.
Severe involvement or special-site disease	Exceptions (e.g., extensive recalcitrant facial, pustular hands/feet, or genital disease interfering with function) may permit earlier consideration of systemic or biologic therapy per the product criteria.

Required prior therapies before Cibinqo	Notes / exceptions
Topical failures	Inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus) AND one high‑potency topical corticosteroid (examples listed in policy: betamethasone dipropionate, mometasone furoate, fluocinonide, clobetasol propionate).
Prior biologic/systemic trials	Inadequate response or intolerance to tralokinumab (Adbry), dupilumab (Dupixent), lebrikizumab (Ebglyss), OR upadacitinib (Rinvoq) is required per the updated Cibinqo criteria before coverage.
Traditional systemic therapy requirement	Also requires inadequate response or intolerance to one traditional systemic therapy (e.g., methotrexate, azathioprine, cyclosporine, mycophenolate mofetil) unless the exception below applies.
Exception allowing substitution	Exception: An individual who has already tried Ebglyss (lebrikizumab) or Nemluvio (nemolizumab) may be exempted from attempting one traditional systemic agent (i.e., Ebglyss or Nemluvio can count in lieu of one traditional systemic therapy trial).

Benefit Routing and Site of Care

Billing Rule

Benefit routing: Adbry may be medical; most others pharmacy

Adbry (tralokinumab-Idrm) may be managed through the medical benefit while most other listed agents (including Cibinqo, Ebglyss, Elidel, Eucrisa, Nemluvio, Opzelura, Protopic, Rinvoq, Vtama, Zoryve) are managed through the pharmacy benefit.

Background — Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by intense pruritus and eczematous lesions. It is associated with Th2 and ILC2 activation and increased cutaneous levels of type 2 cytokines, including IL‑13 and IL‑4. The American Academy of Dermatology recommends a stepwise approach beginning with trigger avoidance, basic skin care and moisturization; when these measures fail, topical corticosteroids and topical calcineurin inhibitors are recommended, with escalation to systemic or targeted therapies for moderate‑to‑severe or refractory disease. Epidemiologic data cited in the policy note approximately 16.5 million US adults had AD in 2012, with a substantial portion experiencing moderate‑to‑severe disease.

Definitions and Drug Summaries

Age considerations

Policy ruleAge limits in this policy follow FDA‑approved indications for each drug

Source statementConsideration of Age: Age limits specified in this policy are determined according to the FDA‑approved indications (prescribing information)

Reference materialsPrescribing information for individual products cited in References (eg, Adbry, Cibinqo, Rinvoq, Ebglyss, Opzelura, Vtama, Nemluvio)

Atopic dermatitis (AD) — definition

DefinitionAtopic dermatitis (AD) is a chronic, inflammatory, relapsing skin condition characterized by significant pruritus and episodic eczematous lesions

PathophysiologyAssociated with inappropriate activation of Th2 and ILC2 cells and increased type 2 cytokines including IL‑13 and IL‑4 in the skin

OpenPayer

Pharmacologic Treatment of Atopic Dermatitis

Coverage Criteria — Atopic Dermatitis Therapies

Coding and Body Surface Area

Provider Actions, Prior Authorization & Documentation

Initial Therapy Requirements

Re-authorization and Maintenance Criteria

Step Therapy Requirements and Prior Trials

Benefit Routing and Site of Care

Background — Atopic Dermatitis

Definitions and Drug Summaries